Huangshan Capsule (002817.SZ) released its semi-annual report on August 16th. The company achieved a revenue of 235.2684 million yuan, a decrease of 7.98% from the same period last year. The net income attributable to shareholders of the listed company was 29.6824 million yuan, a decrease of 21.84% from the same period last year.
The company is a large-scale capsule manufacturer in China that has the production technology and capacity for five major product series, including gelatin empty capsules, enteric gelatin capsules, colon soluble empty capsules, plant-based empty capsules, and plant-based enteric-coated capsules. The company can produce various sizes of capsules, such as 00#, 0# lengthened, 0#, 1# lengthened, 1#, 2#, 3#, 4#, and 5# capsules, with an annual production capacity of more than 40 billion pieces. It is a high-tech enterprise that integrates research and development, production, and marketing. Since its establishment in 1989, the company has always been committed to the mission of "leading the industry, rewarding shareholders, benefiting employees, and promoting the health of the people", and is dedicated to becoming an expert in personalized capsule services and a leading pharmaceutical technology service company in China.
